The post-trial briefs for Amarin and generic filers of Vascepa were filed last Friday, and they read positively for Amarin, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The burden to invalidate all of Amarin's patents is on the generics and they have to prove that the United States Patent and Trademark Office did not do its job correctly in granting all the patents, says the analyst. Chen thinks Amarin "could win and that the generics have a weak case." As a result, the stock's risk/reward is to the upside, contends the analyst. She believes Amarin could trade toward $35 per share in a positive outcome and down to $9-$10 on a negative decision. Chen has an Overweight rating on Amarin with a $35 price target. The stock closed Friday at $14.67.